T Agizew1,2,3, D Surie4, J E Oeltmann4, M Letebele1, S Pals4, U Mathebula1, A Mathoma1, M Kassa5, S Hamda2, P Pono6, G Rankgoane-Pono7, R Boyd1,8, A Auld4, A Finlay1,8. 1. Centers for Disease Control and Prevention (CDC), Gaborone, Botswana. 2. Department of Family Medicine and Public Health, Faculty of Medicine, University of Botswana, Gaborone, Botswana. 3. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4. Division of Global HIV/AIDS and Tuberculosis, CDC, Atlanta, GA, USA. 5. Department of Anaesthesia and Critical Care, University of Botswana, Gaborone, Botswana. 6. Department of HIV/AIDS Prevention and Care, Ministry of Health and Wellness, Gaborone, Botswana. 7. National Tuberculosis Control Programme, Ministry of Health and Wellness, Gaborone, Botswana. 8. Division of Tuberculosis Elimination, CDC, Atlanta, GA, USA.
Abstract
SETTING: Twenty-two clinics providing HIV care and treatment in Botswana where tuberculosis (TB) and HIV comorbidity is as high as 49%. OBJECTIVES: To assess eligibility of TB preventive treatment (TPT) at antiretroviral therapy (ART) initiation and at four follow-up visits (FUVs), and to describe the TB prevalence and associated factors at baseline and yield of TB diagnoses at each FUV. DESIGN: A prospective study of routinely collected data on people living with HIV (PLHIV) enrolled into care for the Xpert® MTB/RIF Package Rollout Evaluation Study between 2012 and 2015. RESULTS: Of 6041 PLHIV initiating ART, eligibility for TPT was 69% (4177/6041) at baseline and 93% (5408/5815); 95% (5234/5514); 96% (4869/5079); and 97% (3925/4055) at FUV1, FUV2, FUV3, and FUV4, respectively. TB prevalence at baseline was 11% and 2%, 3%, 3% and 6% at each subsequent FUV. At baseline, independent risk factors for prevalent TB were CD4 <200 cells/mm3 (aOR = 1.4, P = 0.030); anemia (aOR = 2.39, P < 0.001); cough (aOR = 11.21, P < 0.001); fever (aOR = 2.15, P = 0.001); and weight loss (aOR = 2.60, P = 0.002). CONCLUSION: Eligibility for TPT initiation is higher at visits post-ART initiation, while most cases of active TB were identified at ART initiation. Missed opportunities for TB further compromises TB control effort among PLHIV in Botswana.
SETTING: Twenty-two clinics providing HIV care and treatment in Botswana where tuberculosis (TB) and HIV comorbidity is as high as 49%. OBJECTIVES: To assess eligibility of TB preventive treatment (TPT) at antiretroviral therapy (ART) initiation and at four follow-up visits (FUVs), and to describe the TB prevalence and associated factors at baseline and yield of TB diagnoses at each FUV. DESIGN: A prospective study of routinely collected data on people living with HIV (PLHIV) enrolled into care for the Xpert® MTB/RIF Package Rollout Evaluation Study between 2012 and 2015. RESULTS: Of 6041 PLHIV initiating ART, eligibility for TPT was 69% (4177/6041) at baseline and 93% (5408/5815); 95% (5234/5514); 96% (4869/5079); and 97% (3925/4055) at FUV1, FUV2, FUV3, and FUV4, respectively. TB prevalence at baseline was 11% and 2%, 3%, 3% and 6% at each subsequent FUV. At baseline, independent risk factors for prevalent TB were CD4 <200 cells/mm3 (aOR = 1.4, P = 0.030); anemia (aOR = 2.39, P < 0.001); cough (aOR = 11.21, P < 0.001); fever (aOR = 2.15, P = 0.001); and weight loss (aOR = 2.60, P = 0.002). CONCLUSION: Eligibility for TPT initiation is higher at visits post-ART initiation, while most cases of active TB were identified at ART initiation. Missed opportunities for TB further compromises TB control effort among PLHIV in Botswana.
Authors: Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri Journal: Cochrane Database Syst Rev Date: 2014-01-21
Authors: Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson Journal: N Engl J Med Date: 2019-03-14 Impact factor: 91.245
Authors: Molebogeng X Rangaka; Robert J Wilkinson; Andrew Boulle; Judith R Glynn; Katherine Fielding; Gilles van Cutsem; Katalin A Wilkinson; Rene Goliath; Shaheed Mathee; Eric Goemaere; Gary Maartens Journal: Lancet Date: 2014-05-13 Impact factor: 79.321
Authors: Surbhi Modi; Joseph S Cavanaugh; Ray W Shiraishi; Heather L Alexander; Kimberly D McCarthy; Barbara Burmen; Hellen Muttai; Chad M Heilig; Allyn K Nakashima; Kevin P Cain Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich Journal: PLoS Med Date: 2012-07-24 Impact factor: 11.069
Authors: Kenneth Turinawe; Greet Vandebriel; David W Lowrance; Francois Uwinkindi; Philippe Mutwa; Kimberly R Boer; Grace Mutembayire; David Tugizimana; Sabin Nsanzimana; Eric Pevzner; Andrea A Howard; Michel Gasana Journal: PLoS One Date: 2016-09-29 Impact factor: 3.240
Authors: Carlos Augusto Scacchetti de Almeida; Caio R Dos Santos; Nilson Roberti Benites; Ricardo S Jordão; Érica Chimara; Fernando José Benesi; Sergio S de Azevedo; Márcio Garcia Ribeiro; Sônia Regina Pinheiro Journal: Braz J Microbiol Date: 2021-11-12 Impact factor: 2.476